Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Cadherin 1, Type 1, E-Cadherin (Epithelial) (CDH1) antibody
|Synonyms||uvo, lcam, E-Cad, XBcad, l-cam, xcdh1, cdhc-A, xb-cad, XTCAD-1, E-cadherin, cadherin-1, uvomorulin, XB-cadherin, cdh1|
Alternatives Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC)
|4 references available|
|Quantity||100ug (1mg/ml) (Variants)|
|Price||649.44 $ Plus shipping costs $45.00|
|Immunogen||5H9 is a mouse monoclonal IgG1 antibody obtained by fusion of P3-X63-Ag 8,653 mouse myeloma cells with spleen cells from a BABL/c mouse immunized with affinity purified 80 kD extracellular fragments of E-cadherin derived from tryptic digestion of A-431 human vulva carcinoma cells.|
|Description||Cadherins constitute a family of transmembrane glycoproteins involved in Ca2+-dependent cell-cell interactions. The members of this family are differentially expressed in various tissues. They function in the maintenance of tissue integrity and morphogenesis. Cadherins are divided into type I and type II subgroups. Type I cadherins include epithelial cadherin (E-cadherin, cadherin-1 or uvomorulin), neural cadherin (N-cadherin or cadherin-2), placental cadherin (P-cadherin or cadherin-3) and retinal cadherin (R-cadherin or cadherin-4), whereas kidney cadherin (K-cadherin or cadherin-6) and osteoblast cadherin (OB-cadherin or cadherin-11) are type II cadherins. One of the best characterized cadherins is E-cadherin, a 120 kD transmembrane glycoprotein consisting of an 80 kD extracellular and a 40 kD transmembrane and cytoplasmic part. The extracellular domains of E-cadherin are responsible for calcium binding which allows for homophilic interaction with other E-cadherin molecules on the same cell and neighbouring cells. In addition, E-cadherin can interact heterophilically with integrin E7. The cytoplasmic domain of E-cadherin is linked to the actin cytoskeleton through the associated cytoplasmic catenin proteins, thus establishing a complex localized to adherens junctions. In carcinomas E-cadherin is frequently downregulated, which is consistent with its function of an invasion suppressor in normal epithelia.|
|Specificity||5H9 recognizes both the 120 kD E-cadherin and its 80 kD trypsin-resistant extracellular part.|
|Application Notes||5H9 is suitable for immunoblotting, immunocytochemistry and immunohistochemistry on frozen and paraffin embedded tissues. For frozen tissues use a PBS buffer containing 0.1 mM CaCl2 and 0.1 mM MgCl2. For paraffin embedded tissues use a pretreatment step of 15 minutes incubation in TRIS-EDTA buffer pH 9 in a microwave. Recommended dilution Optimal antibody dilution should be determined by titration, recommended range is 1:50 – 1:100 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:100 – 1:500 for immunoblotting applications.|
|Buffer||Each vial contains 100 ml of 1 mg/ml purified antibody in PBS containing 0.09% sodium azide.|
|Storage||Store at 4°C, or in small aliquots at –20°C|
|Restrictions||For Research Use only|
|anti-Cadherin 1, Type 1, E-Cadherin (Epithelial) (CDH1) antibody|
Frixen, Behrens, Sachs et al.: "E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells." in: The Journal of cell biology, Vol. 113, Issue 1, pp. 173-85, 1991 (PubMed).
Moll, Mitze, Frixen et al.: "Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas." in: The American journal of pathology, Vol. 143, Issue 6, pp. 1731-42, 1994 (PubMed).
Gabbert, Mueller, Schneiders et al.: "Prognostic value of E-cadherin expression in 413 gastric carcinomas." in: International journal of cancer. Journal international du cancer, Vol. 69, Issue 3, pp. 184-9, 1996 (PubMed).
Schwechheimer, Zhou, Birchmeier: "E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas." in: Virchows Archiv : an international journal of pathology, Vol. 432, Issue 2, pp. 163-7, 1998 (PubMed).